Moritz Spangemacher

Mannheim, BW 68159, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Announcing the Lancet Commission on schizophrenia and psychotic disorders.

Announcing the Lancet Commission on schizophrenia and psychotic disorders.

Journal: Lancet (London, England)

Published: April 25, 2026

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.

Journal: JAMA psychiatry

Published: March 18, 2026

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Journal: Psychotherapy and psychosomatics

Published: February 02, 2026

Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression.

Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression.

Journal: Brain, behavior, and immunity

Published: December 04, 2025

Compassionate use of psilocybin for treatment-resistant depression in Germany.

Compassionate use of psilocybin for treatment-resistant depression in Germany.

Journal: The lancet. Psychiatry

Published: August 13, 2025

Rethinking Seizure Termination: A Possible Paradigm Shift in Understanding a Primary Mechanism of ECT.

Rethinking Seizure Termination: A Possible Paradigm Shift in Understanding a Primary Mechanism of ECT.

Journal: The journal of ECT

Published: July 18, 2025

Psychedelics: The pathway to implementation in the European healthcare systems.

Psychedelics: The pathway to implementation in the European healthcare systems.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: May 31, 2025

The sense and nonsense of antipsychotic combinations: A model for dopamine D2/3 receptor occupancy.

The sense and nonsense of antipsychotic combinations: A model for dopamine D2/3 receptor occupancy.

Journal: Translational psychiatry

Published: May 23, 2025

Can antidepressants negatively alter the long-term course of depressive disorders?

Can antidepressants negatively alter the long-term course of depressive disorders?

Journal: Der Nervenarzt

Published: January 10, 2025

Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment

Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment

Journal: Der Nervenarzt

Published: November 20, 2024

Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry.

Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry.

Journal: Deutsches Arzteblatt international

Published: May 19, 2024

Neurovascular coupling of striatal dopamine D2/3 receptor availability and perfusion using simultaneous PET/MR in humans.

Neurovascular coupling of striatal dopamine D2/3 receptor availability and perfusion using simultaneous PET/MR in humans.

Journal: Neuroscience applied

Published: May 13, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026